The longevity space has grown quickly, but most of it has been shaped by male-dominated research and similarly built for male-dominated markets, like performance protocols and high-ticket biohacking. Women, meanwhile, are more likely to face hormonal transitions, autoimmune conditions, chronic fatigue, and brain fog through perimenopause and menopause, with far fewer options built for them.
Wisp, the largest women’s telehealth company in the U.S., just launched its Longevity and Healthy Aging category, a direct move into that gap.
The initial lineup includes five options across three compounds: glutathione (nasal spray and injectable), NAD+ (nasal spray and injectable), and low-dose naltrexone.
The category is designed around a healthspan approach, supporting women starting in their 30s before symptoms escalate into chronic conditions.
Wisp chose to lead with compounds that target what women most commonly experience as they age. Glutathione is one of the body’s most important antioxidants, supporting detoxification, immune function, and oxidative stress. NAD+ plays a central role in cellular energy and mitochondrial function, and naturally declines with age. These declines, the brand says, are linked to fatigue, brain fog, and reduced resilience. The last main ingredient, low-dose naltrexone, is being studied for its role in immune regulation, particularly for inflammation and autoimmune-related symptoms—conditions that also disproportionately affect women.
The thread across all three: cellular repair, energy, and immune balance.
All five treatments are clinician-guided through Wisp’s existing telehealth model. Patients provide medical history through an online consultation, a licensed clinician reviews and prescribes, and care is monitored with ongoing adjustments. Most consultations are asynchronous, with live visits in states that require them.
Wisp’s Longevity and Healthy Aging treatments are available now at hellowisp.com.